In this MedInsights Unleashed episode, we explore an emerging treatment for chronic degenerative disc disease called Hydrafil. Our guests are Bill Niland, CEO of ReGelTec Inc., and Dr. Anthony Lowman, PhD, Professor of Biomedical Engineering and Co-Founder/Chief Medical Officer at ReGelTec. They walk us through the science, creation, and development of this injectable hydrogel technology. Hydrafil is designed to help patients with lumbar back pain by restoring hydration and pressure inside the spinal disc, supporting its structure, and potentially reducing inflammation and pain.

ReGelTec has launched its pivotal HYDRAFIL-D Study, a multicenter, randomized U.S. trial enrolling ~225 patients. For details, visit ClinicalTrials.gov and search: Degenerative Disc Disease + Hydrafil (NCT06011551 and NCT04984629).